相关实验视频

Updated: Jul 28, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

埃里布林甲基酸盐通过CD103产生抗瘤作用

Kazumasa Oya¹, Yoshiyuki Nakamura¹, Rei Watanabe²

¹The Department of Dermatology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

|June 1, 2023

概括

埃里布林甲基酸盐 (ERB) 通过激活T细胞来增强抗瘤免疫力. 这种微管破坏性药物增加了瘤透性淋巴细胞 (TILs),并提高了对ERB至关重要的E-cadherin的调节.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

埃里布林甲基酸盐 (ERB) 是一种合成的哈利孔德林B的模拟物,通过微管破坏抑制瘤细胞的生长.
抗癌药物可以调节瘤微环境,包括免疫反应,但ERB的精确机制尚不清楚.

研究的目的:

阐明ERB影响瘤微环境和免疫反应的机制.
研究T细胞和E-cadherin在ERB抗瘤作用中的作用.

主要方法:

瘤生长抑制在与ERB.治疗的野生型,Rag1缺乏和CD103缺乏小鼠中进行了评估.
进行T细胞枯竭 (CD4+或CD8+),以评估它们在ERB疗效中的作用.
流细胞计用于分析免疫细胞群,激活标记物,免疫检查点分子和瘤透淋巴细胞 (TIL) 中的细胞毒分子.
量化了瘤细胞和TIL中的E-cadherin和CD103表达.

主要成果:

在野生型小鼠中,ERB抑制了MC38结肠癌的生长,但在缺乏T细胞的Rag1小鼠中没有.
CD4+或CD8+T细胞的枯竭取消了ERB的抗瘤作用,突出了T细胞的关键作用.
在TILs中,ERB增加了TILs,上调激活 (CD38,CD69),免疫检查点 (LAG3,TIGIT,Tim3) 和细胞毒性标志物 (granzyme B,perforin).
在瘤细胞中,ERB提高了E-cadherin的调节,并在CD4+和CD8+TIL上增加了CD103的表达.
在缺乏CD103的小鼠中,ERB的抗瘤作用被废除了.

结论:

通过激活CD103+ T细胞,依赖于瘤细胞中的E-cadherin表达,ERB通过激活CD103+ T细胞发挥抗瘤作用.
ERB调节瘤微环境,增强T细胞介导的抗瘤免疫力.

关键词:

CD103 是一个CD103 CD103 是一个CD103 它具有抗瘤效果的作用.埃里布林梅西酸盐是什么免疫检查点是一个检查点.定居记忆T细胞是T细胞.

更多相关视频

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...